Is DNA or EDIT more undervalued in 2026?

CirclFi compares Ginkgo Bioworks Holdings, Inc. (DNA) and Editas Medicine, Inc. (EDIT) using 13 institutional-grade valuation models. DNA has a Quality of Company score of 6.1/10 while EDIT scores 6.5/10.

Which is a better buy — DNA or EDIT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DNA and EDIT valuations compare?

DNA at $9.37 and EDIT at $3.46 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DNA vs EDIT Valuation Comparison 2026 — Intrinsic Value Analysis

DNA

Biological Products, (No Diagnostic Substances)

Ginkgo Bioworks Holdings, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$9.37

Last close

Models

10/13

Active

EDIT

Biological Products, (No Diagnostic Substances)

Editas Medicine, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$3.46

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	DNA Fair Value	DNA Upside	EDIT Fair Value	EDIT Upside
Bayesian DCF	Intrinsic	$0.13	-98.6%	$1.06	-69.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.29	-64.9%	$2.00	-42.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DNA vs EDIT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DNA vs EDIT — Which Stock Is More Undervalued?

EDIT scores higher with a 6.5/10 quality rating vs DNA's 6.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Ginkgo Bioworks Holdings, Inc. (DNA) and Editas Medicine, Inc. (EDIT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DNA currently trades at $9.37 with a QOC of 6.1/10, while EDIT trades at $3.46 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).